Sangamo Therapeutics

Company Overview

Founded in 1995, Sangamo is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of engineered zinc finger DNA-binding proteins (ZFPs) as novel ZFP Therapeutics targeting various diseases with unmet medical needs.

The company’s zinc finger epigenetic regulators show great promise in addressing debilitating neurological disorders, and its capsid engineering platform has shown the potential to enhance delivery capabilities beyond existing intrathecal delivery methods, including reaching the central nervous system (CNS)in preclinical studies.

In 2023, Sangamo announced its strategic shift to focus on neurology, developing epigenetic regulation therapies for serious neurological diseases and advancing novel AAV capsid delivery technology. As part of this transformation, the company decided to pause new investments in Fabry gene therapy and CAR-Treg cell therapy programs unless it secures a collaboration partner or external funding. Additionally, Sangamo has restructured its operations and reduced its workforce, consolidating all U.S. operations, including the headquarters, to the Richmond, California facility and planning to close other facilities in Brisbane, California, and Valbonne, France, in 2024.

Financial Highlights (FY 2024)

Company's Business Segments

• Science : The company generates revenue through several technology platforms such as the Zinc Finger Platform, Delivery Platform, Modular Integrase (MINT) Platform in the field of Neurology and Oncology.
• Programs : Clinical programs for Hemophilia A, Fabry Disease.